Antibodies against Synaptic Proteins

Monoclonal Antibodies that are Reactive against a Range of Synaptic Proteins

Advantages

  • Enables the probing of synaptic protein changes and distribution in many neurological applications
  • Antibodies against synaptic proteins can be used to develop new therapies for neurological diseases

Technology Details

Most pharmacological approaches to neuropsychiatric disorders involve attempts to block postsynaptic receptors or inhibit presynaptic neurotransmitter uptake.  Recent work indicates that families of proteins are involved in the presynaptic mechanisms of neurotransmitter secretion.

Antibodies reactive with these proteins can be used to demonstrate alterations in presynaptic mechanisms in a wide range of neuropsychiatric disorders.  Certain synaptic proteins are susceptible to the action of neurotoxins.  The use of anti-synaptic antibodies as probes into the mechanisms of illness, and as reagents to permit characterization of presynaptic proteins may lead to the development of new therapeutics.  For example, this research tool may lead to entirely new therapeutic strategies for Alzheimer’s disease, temporal lobe epilepsy and schizophrenia.

The antibodies SP15 and SP17 are reactive with synaptophysin expressed in CHO cells. Antibodies EP10, SP3, SP4 and SP16 have been used in peptidase digestion and deglycosylation studies, and appear to be reactive with native synaptophysin, although not with the recombinant molecule.  Antibody SP10 is reactive with VAMP-1 (aa 1-118) and VAMP-2 (aa 33-96) fusion protein expressed in a bacterial system.  In immunocytochemical and immunoblotting studies, SP11 appears identical to SP10; however, SP11 is not reactive with bacterially expressed fusion protein.  Antibodies SP12 and SP14 are reactive with SNAP-25 (A and B isoforms) fusion protein from COS cells, but not with fusion protein from bacterial systems.  Antibodies SP5, SP6, SP7, SP8 and FP20 are reactive with syntaxin (1A aa 4-190) expressed in bacterial systems.  Antibody SP18 reacts with recombinant CDC-rel1, but not CDC-rel2 expressed in a bacterial system. SP19 and SP20 appear to be similar but have not been tested as extensively.